Threads / MHRA Patient Engagement Policy / How should we engage and involve patients and the public in…
Consultation Outcome Published 15 Jun 2020 Medicines and Healthcare products Regulatory Agency ↗ View on GOV.UK

How should we engage and involve patients and the public in our work

Work is ongoing to address the comments and feedback from respondents to the consultation. Publication of our report on the consultation has been delayed in light of the Agency’s response during the ongoing coronavirus situation.

Opened 15 Jul 2019
Closed 7 Oct 2019
▤ Verbatim text from source document

We want to adopt a more systematic approach to listening to and involving patients – ensuring that the patient voice is heard when safety issues, concerning medicines or medical devices, are identified and in the licensing of new medicines.

We also plan to do more to communicate about who we are and the results of our work.

We would like to hear from:

  • patients
  • patient group representatives
  • carers
  • healthcare professionals

By taking part you will help us identify what our priorities should be for patient engagement and involvement in the future.

Engagement activities

To support the consultation we held engagement events in September and October in Belfast, Cardiff, Glasgow and London.